According to the lawsuit, Fastin contains dimethylamylamine (DMAA) an amphetamine-like product which is considered dangerous, because it narrows blood vessels and arteries, and due to its adverse health effects, such a rapid heartbeat, is illegal. The FDA has ruled that it may not be used as an active ingredient in a dietary supplement.
The lawsuit claims that the manufacturers fail to mention that its product contains DMAA. "Defendant's advertising statements, which fail to mention the risks associated with this ingredient, are both false and misleading to consumers," the lawsuit states.
Instead, the product advertising claims "Fastin will help you lose weight and feel great!" The defendant also claims that Fastin is "probably the cleanest stimulant ever created."
"Before marketing a Product containing DMAA, manufacturers and distributors have a responsibility under the law to provide evidence of the safety of its Product. Defendant has failed to do that, which made Fastin adulterated" and unlawfully on the market, the lawsuit states.
The Fastin DMAA class action lawsuit is brought by the lawfirm of Kirtland & Packard, on behalf of a proposed class of all U.S. citizens or residents who purchased Fastin within the past four years. It is seeking injunctive relief as well as restitution and disgorgement, statutory damages, general damages, special damages, attorneys' fees and costs.